Factors Affecting Second-Line Therapy Choices in HCC
Wasif M. Saif, MD, discusses available novel therapies for hepatocelluclar carcinoma.
Wasif M. Saif, MD, deputy physician in chief at Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, discusses available novel therapies for treating hepatocelluclar carcinoma (HCC) in the second-line setting.
HCC is a heterogenous disease and difficult to treat, according to Saif, but there are now multiple agents available to treat patients who have failed first-line therapy, including 3 targeted agentsregorafenib (Stivarga), cabozantinib (Cabometyx), and ramucirumab (Cyramza)—and 2 immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda). However, there are no randomized data to inform oncologists which patient is right for each agent.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
